Overview of the development pipeline for chronic induced urticaria

According to DelveInsight's analysis, the chronic induced urticaria treatment pipeline includes at least four leading companies actively developing four or more innovative chronic induced urticaria treatment solutions.

Understanding Chronic Induced Urticaria:

Chronic inducible urticaria (CIndU) is a type of persistent urticaria that is triggered by certain physical or environmental stimuli (pressure, temperature fluctuations, sun exposure, physical activity, etc.). Unlike chronic idiopathic urticaria, which develops without any obvious cause, CIndU develops from a clear trigger, making it less predictable and harder to control.

The disease is caused by an exaggerated immune response, in which mast cells respond to triggers by releasing histamine and other inflammatory substances, resulting in pruritus, erythema, and edema. Treatment generally involves antihistamines, leukotriene receptor antagonists, and in complex cases, immunomodulatory therapy with an emphasis on suppressing symptoms.

To access the comprehensive Chronic Induced Urticaria pipeline analysis report, https://www.delveinsight.com/report-store/chronic-inducible-urticaria-pipeline-insight?utm_source=prutm_medium=promotionutm_campaign=kkpr

DelveInsight's "Chronic Induced Urticaria Pipeline Analysis 2025" provides an extensive assessment of current clinical research initiatives and market expansion potential in the chronic induced urticaria treatment space.

Key results from the chronic induced urticaria pipeline analysis

DelveInsight's chronic induced urticaria pipeline assessment reveals a dynamic field characterized by 4+ active participants developing 4+ therapeutic solutions for the management of chronic induced urticaria.
Leading chronic induced urticaria research organizations, including Celldex Therapeutics, Jasper Therapeutics, and others, are investigating new medications to enhance treatment options for chronic induced urticaria.
Notable treatment candidates for chronic induced urticaria in various stages of development include varzolvolimab.

Recent advances in chronic induced urticaria pipeline development:

In December 2024, Jasper Therapeutics announced preliminary findings from the Phase 1b/2a SPOTLIGHT study evaluating burquilimab, a mast cell-targeting monoclonal antibody. CIndU patients experienced rapid and remarkable responses, with 93% achieving partial or complete improvement within six weeks. The intervention was well-received, with no serious side effects reported. These findings indicate that burquilimab may be an innovative treatment option for CIndU.

Nemolizumab, an interleukin-31 receptor inhibitor, was approved by the U.S. Food and Drug Administration (FDA) in August 2024 and the European Union (EU) in February 2025. Nemolizumab inhibits IL-31-mediated responses, thereby suppressing the release of inflammatory cytokines and chemokines. Its main indications include atopic dermatitis, but its mechanism of action may provide insight into the potential applications of CIndU in the future.

In October 2024, Celldex Therapeutics announced positive results from a Phase II clinical trial of varzolvolimab, a humanized monoclonal antibody targeting the KIT receptor tyrosine kinase. The trial achieved all primary and secondary endpoints with high statistical significance and demonstrated a favorable safety and tolerability profile. These results represent the first demonstration of clinical efficacy in a large-scale randomized placebo-controlled study of CIndU, and Celldex plans to initiate a Phase III trial in 2025.

Chronic Induced Urticaria Pipeline Test

The analysis includes:

A comprehensive assessment of leading organizations developing drugs to treat chronic induced urticaria
Evaluating various treatment options in early, mid, and advanced stages of treatment development for chronic induced urticaria
Analysis of major organizations engaged in targeted drug development and their corresponding active and inactive (paused or terminated) efforts
Navigation of investigational new drugs based on development stage, route of administration, target mechanism, monotherapy or combination therapy, various modes of action, and molecular classification
To thoroughly examine partnerships (industry and academia), license agreements, and financing details for the future market development of chronic induced urticaria

Download Free Sample of Chronic Induced Urticaria Pipeline Report: https://www.delveinsight.com/sample-request/chronic-inducible-urticaria-pipeline-insight?utm_source=prutm_medium=promotionutm_campaign=kkpr

A new treatment for chronic induced urticaria

Valzorvolimab: Celldex Therapeutics

Valzolvolimab is a humanized monoclonal antibody developed by Celdex Therapeutics for the treatment of inflammatory and allergic diseases. The drug selectively binds with high specificity to the receptor tyrosine kinase KIT and effectively inhibits its function, which is essential for mast cell function and survival. Mast cells play a pivotal role in inflammatory responses, including hypersensitivity and allergic reactions, making this inhibitor useful in managing these conditions. Valzolvolimab is currently in Phase II clinical trials for the treatment of chronic induced urticaria.

Chronic Induced Urticaria Research Institute

Several prominent companies are currently working on developing treatments for chronic induced urticaria, most notably Celldex Therapeutics, which has the most advanced therapeutic candidate currently in Phase II clinical trials.

DelveInsight's analysis covers approximately four or more products across various stages of clinical development:

Advanced stage products (Phase III) Intermediate stage products (Phase II) Early Stage Products (Phase I)Comprehensive DetailsPreclinical and discovery stage candidates Terminated and Inactive Candidates

The chronic induced urticaria pipeline analysis evaluates the therapeutic efficacy of drugs in development by route of administration. Products are organized by route of administration as follows:

Intravenous
Subcutaneous
Oral
Intramuscular

Chronic induced urticaria products fall into various molecular categories, including:

Monoclonal antibodies
Small molecules
peptide

Visit our sample page for comprehensive assessment of emerging treatments for Chronic Induced Urticaria and key players:Chronic Induced Urticaria Clinical Research and Development@ https://www.delveinsight.com/report-store/chronic-inducible-urticaria-pipeline-insight?utm_source=prutm_medium=promotionutm_campaign=kkpr

Chronic Induced Urticaria Pipeline Treatment Evaluation

Chronic Induced Urticaria Analysis by Product Category
Chronic induced urticaria by developmental stage
Analysis of chronically induced urticaria by route of administration
Analysis of chronically induced urticaria by molecular classification

Download the sample analysis of Chronic Induced Urticaria to get more information on the Chronic Induced Urticaria Treatment market. https://www.delveinsight.com/sample-request/chronic-inducible-urticaria-pipeline-insight?utm_source=prutm_medium=promotionutm_campaign=kkpr

Report Structure

Report Overview
Executive Analysis
Current treatments for chronic induced urticaria
Chronic Induced Urticaria – A DelveInsight Research Perspective
Treatment evaluation
Advanced drug for chronic induced urticaria (Phase III)
Drug for chronic moderate-to-severe urticaria (Phase II)
Early Stage Products (Phase I)
Preclinical and Discovery Stage Products
Inactive Products
Dormant Products
Discontinuation of medication for chronic urticaria
Chronic Induced Urticaria Product Analysis
Leading Treatment Company for Chronic Induced Urticaria
Primary Chronic Induced Urticaria Products
Dormant and discontinued products
Unresolved requirements for chronically induced urticaria
Future prospects for chronic induced urticaria
Expert analysis of chronic induced urticaria
Supplementary Material
Research Methods

Request Sample PDF for Comprehensive Chronic Induced Urticaria Pipeline Report Details. https://www.delveinsight.com/report-store/chronic-inducible-urticaria-pipeline-insight?utm_source=prutm_medium=promotionutm_campaign=kkpr

About DelveInsight

DelveInsight is a leading business advisory and market analytics firm focused on the life sciences sector, empowering pharmaceutical companies with comprehensive, integrated solutions aimed at improving operational performance.